Latest Breaking News On - Allogeneic car development programs - Page 1 : comparemela.com

Cellectis Reports Financial Results for First Quarter 2024

• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca

United kingdomNorth carolinaUnited statesFrance generalNew yorkMarc dunoyerPatricia sosa navarroArthur strilAshleyr robinsonPascalyne wilsonBing wangResearch planAllogeneic car development programsGroup shareInternational accounting standards boardEuropean union

Cellectis Reports Financial Results for First Quarter 2024

Cellectis Reports Financial Results for First Quarter 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesNorth carolinaUnited kingdomNew yorkFrance generalPatricia sosa navarroBing wangArthur strilAshleyr robinsonMarc dunoyerPascalyne wilsonAllogeneic car development programsResearch planCellectis the company euronext growthGroup shareInternational financial reporting standards

Cellectis Reports Financial Results For First Quarter 2024

. Cellectis announced completion of the additional equity investment of $140M by AstraZeneca . Cash position of $143 million as of March 31

United statesUnited kingdomMarc dunoyerBing wangInternational accounting standards boardCellectis the company euronext growthAllogeneic car development programsEuropean unionResearch planInternational financial reporting standardsEuronext growthChief executive officerDevelopment programsInvestment agreementsArthur strilInterim chief financial officer

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

• Preliminary results of NATHALI-01 and updated results of BALLI-01 Phase I clinical studies presented at the American Society of Hematology 65th Annual Meeting • Execution of strategic.

New yorkUnited statesFrance generalNorth carolinaBingc wangPascalyne wilsonArthur strilAllogene alloAnnick schwebigAshleyr robinsonMarc dunoyerPatricia sosa navarroAmerican society of geneTaz holdingsEuropean hematology associationCalyxt inc

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

• Strategic Collaboration and Investment Agreements signed with AstraZenecaUpdated results of the Phase I BALLI-01 Trial evaluating UCART22 in r/.

United statesNew yorkFrance generalNorth carolinaArthur strilLes laboratoires servierPatricia sosa navarroAshleyr robinsonAllogeneic car development programsMd anderson cancer centerInternational financial reporting standardsAllogene therapeutics incCellectis the company euronext growthCibus globalGroup shareEuropean society